QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
QQQ   324.08 (-0.57%)
AAPL   168.49 (-0.44%)
MSFT   287.02 (-0.74%)
META   177.49 (-0.48%)
GOOGL   118.84 (-0.72%)
AMZN   140.64 (-1.44%)
TSLA   859.89 (-2.62%)
NVDA   179.42 (-0.86%)
NIO   20.82 (+3.84%)
BABA   94.87 (+2.64%)
AMD   98.12 (-0.94%)
MU   62.32 (+1.50%)
T   18.04 (+0.17%)
CGC   3.15 (-4.26%)
GE   78.90 (+2.28%)
F   15.83 (+2.13%)
DIS   117.69 (+4.68%)
AMC   25.46 (+7.56%)
PYPL   99.11 (+0.20%)
PFE   48.29 (-3.32%)
NFLX   242.70 (-0.58%)
NASDAQ:AMRS

Amyris - AMRS Stock Forecast, Price & News

$3.15
-0.10 (-3.08%)
(As of 08/11/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.10
$4.00
50-Day Range
$1.70
$3.25
52-Week Range
$1.47
$16.31
Volume
22.75 million shs
Average Volume
6.17 million shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.17

Amyris MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
286.2% Upside
$12.17 Price Target
Short Interest
Bearish
15.28% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.12mentions of Amyris in the last 14 days
Based on 22 Articles This Week
Insider Trading
Selling Shares
$403,182 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.07) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Basic Materials Sector

105th out of 172 stocks

Industrial Organic Chemicals Industry

10th out of 21 stocks

AMRS stock logo

About Amyris (NASDAQ:AMRS) Stock

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. began coverage on shares of Amyris in a research report on Friday, June 24th. They issued a "neutral" rating for the company. Roth Capital downgraded Amyris from a "buy" rating to a "neutral" rating in a report on Wednesday. Finally, Piper Sandler began coverage on Amyris in a report on Wednesday, May 25th. They set a "neutral" rating and a $2.50 price target on the stock.

Amyris Stock Up 41.9 %

Amyris stock opened at $3.25 on Thursday. Amyris has a 1 year low of $1.47 and a 1 year high of $16.31. The business has a 50-day moving average of $2.05 and a 200-day moving average of $3.27. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.46 and a current ratio of 1.77.

Amyris (NASDAQ:AMRS - Get Rating) last issued its quarterly earnings data on Tuesday, August 9th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06). The company had revenue of $65.20 million during the quarter, compared to analyst estimates of $81.53 million. During the same period in the previous year, the company earned ($0.16) EPS. The business's revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, sell-side analysts expect that Amyris will post -1.07 EPS for the current year.

Insider Activity at Amyris

In other Amyris news, insider Nicole Kelsey sold 94,033 shares of the company's stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $1.80, for a total value of $169,259.40. Following the transaction, the insider now directly owns 63,333 shares of the company's stock, valued at approximately $113,999.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, insider Nicole Kelsey sold 94,033 shares of the stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $1.80, for a total value of $169,259.40. Following the completion of the transaction, the insider now owns 63,333 shares of the company's stock, valued at approximately $113,999.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Hermanus Kieftenbeld sold 34,905 shares of the business's stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $2.34, for a total transaction of $81,677.70. Following the completion of the transaction, the chief financial officer now owns 266,655 shares in the company, valued at approximately $623,972.70. The disclosure for this sale can be found here. In the last quarter, insiders have sold 199,225 shares of company stock worth $403,182. Company insiders own 33.80% of the company's stock.

Receive AMRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amyris and its competitors with MarketBeat's FREE daily newsletter.

AMRS Stock News Headlines

Amyris (NASDAQ:AMRS) Shares Gap Up to $2.32
Amyris (AMRS) Q2 2022 Earnings Call Transcript
Amyris (AMRS) Scheduled to Post Earnings on Tuesday
Amyris (NASDAQ:AMRS) Trading Up 6.8%
See More Headlines
Receive AMRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amyris and its competitors with MarketBeat's FREE daily newsletter.

AMRS Company Calendar

Last Earnings
8/09/2022
Today
8/11/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
Oil & Gas Refining & Marketing
Current Symbol
NASDAQ:AMRS
CUSIP
03236M10
Employees
980
Year Founded
2003

Price Target and Rating

Average Stock Price Forecast
$12.17
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$2.50
Forecasted Upside/Downside
+286.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-270,970,000.00
Pretax Margin
-41.40%

Debt

Sales & Book Value

Annual Sales
$341.82 million
Book Value
$0.80 per share

Miscellaneous

Free Float
211,651,000
Market Cap
$1.01 billion
Optionable
Optionable
Beta
1.62

Social Links















AMRS Stock - Frequently Asked Questions

Should I buy or sell Amyris stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRS, but not buy additional shares or sell existing shares.
View AMRS analyst ratings
or view top-rated stocks.

What is Amyris' stock price forecast for 2022?

3 equities research analysts have issued 1 year target prices for Amyris' stock. Their AMRS share price forecasts range from $2.50 to $19.00. On average, they predict the company's stock price to reach $12.17 in the next year. This suggests a possible upside of 273.2% from the stock's current price.
View analysts price targets for AMRS
or view top-rated stocks among Wall Street analysts.

How have AMRS shares performed in 2022?

Amyris' stock was trading at $5.41 on January 1st, 2022. Since then, AMRS shares have decreased by 39.7% and is now trading at $3.26.
View the best growth stocks for 2022 here
.

When is Amyris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AMRS earnings forecast
.

How were Amyris' earnings last quarter?

Amyris, Inc. (NASDAQ:AMRS) announced its quarterly earnings results on Tuesday, August, 9th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.06. The biotechnology company had revenue of $65.20 million for the quarter, compared to analysts' expectations of $81.53 million. Amyris's quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.16) earnings per share.

When did Amyris' stock split?

Amyris's stock reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is John Melo's approval rating as Amyris' CEO?

84 employees have rated Amyris Chief Executive Officer John Melo on Glassdoor.com. John Melo has an approval rating of 54% among the company's employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Amyris to a friend.

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia Oyj (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Who are Amyris' major shareholders?

Amyris' stock is owned by many different institutional and retail investors. Top institutional shareholders include State of Michigan Retirement System (2.05%), Pinnacle Associates Ltd. (1.42%), JPMorgan Chase & Co. (0.80%), IQ EQ FUND MANAGEMENT IRELAND Ltd (0.46%), Baird Financial Group Inc. (0.31%) and Wolverine Asset Management LLC (0.00%). Insiders that own company stock include Anthony Hughes, Eduardo Alvarez, Frank Kung, Hermanus Kieftenbeld, James F Mccann, John Melo, L John Doerr, Nicole Kelsey and Patrick Y Yang.
View institutional ownership trends
.

How do I buy shares of Amyris?

Shares of AMRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $3.26.

How much money does Amyris make?

Amyris (NASDAQ:AMRS) has a market capitalization of $1.04 billion and generates $341.82 million in revenue each year. The biotechnology company earns $-270,970,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

How many employees does Amyris have?

The company employs 980 workers across the globe.

When was Amyris founded?

Amyris was founded in 2003.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The official website for the company is amyris.com. The biotechnology company can be reached via phone at (510) 450-0761, via email at investor@amyris.com, or via fax at 510-225-2645.

This page (NASDAQ:AMRS) was last updated on 8/11/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.